Schlick Konstantin, Hohla Florian, Hamacher Frank, Hackl Hubert, Hufnagl Clemens, Markus Steiner, Magnes Teresa, Gampenrieder Simon Peter, Melchardt Thomas, Stättner Stefan, Hauser-Kronberger Cornelia, Greil Richard, Rinnerthaler Gabriel
IIIrd Medical Department with Hematology & Medical Oncology, Hemostaseology, Rheumatology & Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Müllner Hauptstrasse 48, Salzburg 5020, Austria.
Salzburg Cancer Research Institute with Laboratory of Immunological & Molecular Cancer Research & Center for Clinical Cancer & Immunology Trials, Salzburg, Austria.
Future Sci OA. 2020 Nov 30;7(2):FSO644. doi: 10.2144/fsoa-2020-0128.
FOLFIRINOX is superior to gemcitabine in patients with pancreatic cancer, but this regimen is associated with toxicity and biomarkers for response are warranted. MicroRNAs can mediate drug resistance and could provide predictive information. Altered expressions of several microRNAs including miR-21-5p, miR-10b-5p and miR-34a-5p have been previously linked to a worse response to gemcitabine. We investigated the influence of expression levels in tumor tissue of those three microRNAs on outcome to FOLFIRINOX. Twenty-nine patients with sufficient formalin-fixed paraffin-embedded tumor tissue were identified. There was no significant association between high and low expression groups for these three microRNA. We conclude that polychemotherapy combination can overcome intrinsic negative prognostic factors.
FOLFIRINOX方案在胰腺癌患者中优于吉西他滨，但该方案存在毒性，因此有必要寻找预测反应的生物标志物。微小RNA可介导耐药性，并可提供预测信息。先前已发现包括miR-21-5p、miR-10b-5p和miR-34a-5p在内的几种微小RNA的表达改变与吉西他滨疗效较差有关。我们研究了这三种微小RNA在肿瘤组织中的表达水平对FOLFIRINOX方案疗效的影响。确定了29例有足够福尔马林固定石蜡包埋肿瘤组织的患者。这三种微小RNA的高表达组和低表达组之间无显著相关性。我们得出结论，多药联合化疗可以克服内在的不良预后因素。
